qnexa

In a surprise move Tuesday, the FDA rejected Orexigen's proposed new diet drug Contrave, saying the company needed to run another study of its cardiovascular risks. With this rejection, all three of a slate of similar diet drugs from competing pharmaceuticals have been turned back by the agency.

After the U.S. Food and Drug Administration rejected two other weight-loss pills earlier this year, an advisory panel has recommended the approval of Orexigen Therapeutics's Contrave. If the FDA follows the recommendation, Contrave could become the first diet drug to win approval in a decade.

It's a busy day at the FDA today as panels meet to discuss two new drugs -- one to help weight loss and the other to combat drug addiction -- and decide whether to approve AstraZeneca's new blood thinner medication.

Pharmaceutical company Vivus is getting hammered in Friday tading, sinking more than 50% in the wake of Thursday's vote by an FDA advisory panel against approving its weight-loss drug, Qnexa, based on safety concerns.

Pharmaceutical company Vivus and investors waited anxiously Thursday for the vote of an FDA advisory panel on the weight-loss drug Qnexa. The verdict is in, and by a vote of 9 to 7, panelists didn't support approving the drug as an obesity treatment.

Arena Pharmaceuticals shares are soaring over 20% in afternoon trading. Arena released study results Wednesday showing its obesity drug lorcaserin helped patients lose weight and keep it off.

An expert panel will review Vivus' potential blockbuster drug Qnexa on Thursday, with the FDA making a decision in October. The FDA acknowledges the drug's effectiveness in cutting weight, but Qnexa will certainly draw scrutiny over its side effects.

On NBC's hit series The Biggest Loser, obese contestants must huff and puff through weeks of endless push-ups, sit-ups and treadmill sprints in hopes of shedding more pounds than their rivals. But with all the sweat and tears required to go from fat to fabulous, many other plus-sized people are...

When a pharmaceutical company announces strong results in late stage studies for a drug for a yet untapped market estimated to be worth billions, the Street reacts. Drugmaker Vivus Inc. (VVUS) found out exactly what's that like when it announced Wednesday its obesity drug candidate Qnexa helped...